RxDoctor Payments Data

Mohit Manandhar, MD

Psychiatry · Baltimore, MDNPI 1053624361

Payments from drug & device makers

$580in general payments, 2019–2025

Across 22 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$135
  • Lundbeck LLC$93
  • Neurocrine Biosciences, Inc.$83
  • Teva Pharmaceuticals USA, Inc.$70
  • Indivior Inc.$61
  • AbbVie$38
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$580 in reported general payments places this provider in the 70th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Medicare billing

Part B allowed, 2024
$8,741
Medicare patients
34
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine27$169,471
Aripiprazole60$5,613
Chlorpromazine Hcl18$3,775
Lurasidone Hcl33$2,972
Clozapine25$2,780
Bupropion XlBupropion Hcl91$2,421
Paliperidone ErPaliperidone12$2,215
Quetiapine Fumarate77$2,065
Desvenlafaxine Succinate ErDesvenlafaxine Succinate42$1,715
Duloxetine Hcl55$1,348
Divalproex Sodium ErDivalproex Sodium16$1,335
Ramelteon15$1,315
Trazodone Hcl94$1,184
Clonazepam167$1,125
Mirtazapine56$1,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$70$169,47127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →